EVIDENCE BASE OF SITAGLIPTIN CLINICAL USE. 10 YEARS IN THE MARKET OF THE WORLD

Authors

  • Kravchun N. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2016.2.11

Keywords:

type 2 diabetes mellitus, sitagliptin, cardiovascular safety

Abstract

A review of the scientific literature about treatment of patients with type 2 diabetes mellitus with the help of the first approved drug from the group of DPP-4 inhibitor sitagliptin was presented. The effects of the treatment of sitagliptin on carbohydrate metabolism, bone metabolism, evaluation of cardiovascular safety were given.

References

Dedov II. Shestakova MV. Inkretiny: novaja veha v lechenii saharnogo diabeta 2 tipa, Moskva, 2010: 92 p.

Chan J C, Scott R, Ferreira AJC, et al. Diabetes Obes Metab 2008; 10(7):545-555.

Deacon CF. Diabetes Obes Metab 2011; 13:7-18.

Deacon CF, Holst JJ. Expert Opin Drug Saf 2013;14(15):1-7.

Mkrtumjan AM, Birjukova EV, Morozova IA. Poliklinika 2015; 1:63-70.

Mkrtumjan AM, Birjukova EV. Saharnyj Diabet 2005; 31(2):34-41.

Shestakova MV. Saharnyj Diabet 2010; 3:57-60.

Ahr B. Targets and Therapy 2010; 3;31-41.

Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Diabetes Obes Metab 2010; 12(2):167-177.

Williams-Herman D, Xu L, Teng R, et al. Diabetes Obes Metab 2012; 14(1):67-76.

Valensi P, et al. Diab Metab 2015; 41(3):231-238.

Eurich DT, Simpson S, Senthilselvan A, et al. BMJ 2013; 25:346.

Murai K, Katsuno T, Miyagawa JI, et al. Japan Drugs RD 2014; 14(4):301-308.

Herman GA, Bergman A, Stevens C, et al. J Clin Endocrinol Metab 2006; 91:4612-4619.

Gault VA, Lennox R, Flatt PR. Diabetes Obes Metab 2015; 28:208-215.

Shankar RR, Xu L, Golm GT, et al. Engel Int J Clin Pract 2015; 69(6):626-631.

Hegazy SK. J Bone Miner Metab 2015; 33(2):207-212.

Derosa G, D’Angelo A, Maffioli P. Pharmacol Res 2015; 100:127-134.

Trial evaluating cardiovascular outcomes with sitagliptin, available at: http://www.dtu.ox.ac.uk/tecos/protocol.php.

Sitagliptin cardiovascular outcome study (0431-082 AM1) (TECOS), available at: http://clinicaltrials.gov/ct2/show/NCT00790205.

DOSM. Diabet, Ozhyrinnja, Metabolichnyj Syndrom 2015; 4(IV):10-16.

IMS Health, Total Patient Tracker. Year 2015. Extracted January 2016.

Downloads

Published

2016-06-08

How to Cite

Kravchun, N. (2016). EVIDENCE BASE OF SITAGLIPTIN CLINICAL USE. 10 YEARS IN THE MARKET OF THE WORLD. Problems of Endocrine Pathology, 56(2), 74-79. https://doi.org/10.21856/j-PEP.2016.2.11